他汀类联合心血管药物在冠心病治疗中的应用价值

Clinical value of stanins combined cardiovascular drugs in treatment of coronary heart disease

目的探讨分析他汀类联合心血管药物在冠心病治疗中的应用价值。方法本研究选取2013年2月～2016年1月我院收治的110例冠心病患者作为研究对象，随机分为观察组和对照组，各55例；对照组给予常规心血管类药物进行治疗，观察组在对照组基础上加用他汀类药物进行治疗，两组患者均治疗2个月；治疗前后对两组患者血脂四项水平及治疗效果进行对比分析。结果经治疗后两组患者显效率和有效率比较均无显著差异（P均〉0．05），但观察组治疗总有效率显著高于对照组（96．36％VS74．55％，P〈0．05）；与治疗前相比，经治疗后两组患者血脂四项水平均得到显著改善（P均〈0．05），且观察组改善情况显著优于对照组（P均〈0．05）。结论他汀类联合心血管药物用于冠心病患者的治疗可显著提高治疗效果并改善患者血脂四项水平，值得临床推广应用。

Objective To explore the clinical value of stanins combined cardiovascular drug in treatment of coronary heart disease. Methods 110 cases of coronary heart disease in our hospital From Feb. 2013 to Jan. 2016 were selected and randomly divided into observation group and control group with 30 cases of each group. Patients in control group were treated with cardiovascular drug, and patients in observation group were treated with stanins combined cardiovascular drug. After 2 months of treatment, the level of TCH, TG, HDL-C, LDL-C, and clinical effect of the two groups before and after treatment were compared. Results There was no significant difference on efficiency and effective rate of the two groups before and after treatment （P 〉 0.05）. But the total effective rate in observation group was higher than control group, and the difference was significant （96.36% Vs. 74.55%, P 〈 0.05）. After treatment, the level of TCH, TG, HDL-C, LDL-C in the two groups were improved significantly （P 〈 0.05）. But the improved condition in observation group was higher than that in control group, and the difference was significant （P 〈 0.05）. Conclusion Stanins combined cardiovascular drug in treatment of coronary heart disease can increase the clinical curative effects, and improve the level of TCH, TG, HDL-C, and LDL-C. It was worthy to be clinically popularized and applied.